1 |
NCT01610843 |
Recruiting |
Worldwide Sarcoidosis Research Study |
|
|
Observational |
|
- University of Iowa
- National Center for Research Resources (NCRR)
|
Other / NIH |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Define and characterize sarcoidosis phenotypes and methods of care
|
10000 |
All |
18 Years and older (Adult, Senior) |
NCT01610843 |
200907757 5UL1RR024979 |
WISE |
December 2011 |
December 2020 |
December 2020 |
June 4, 2012 |
March 30, 2017 |
|
- University of Iowa
Iowa City, Iowa, United States
|
2 |
NCT01477359 |
Recruiting |
Cardiac Sarcoidosis Multi-Center Prospective Cohort |
|
|
Observational |
|
- Ottawa Heart Institute Research Corporation
- Ontario Ministry of Health and Long Term Care
- Canadian Institutes of Health Research (CIHR)
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Clinically Manifest Patients
- Clinically Silent and Control Patients
- total mortality
- (and 7 more...)
|
1500 |
All |
18 Years to 99 Years (Adult, Senior) |
NCT01477359 |
UOHI-04 |
CHASM-CS |
August 2012 |
December 2025 |
December 2025 |
November 22, 2011 |
November 22, 2017 |
|
- Libin Cardiovascular Institute of Alberta
Calgary, Alberta, Canada - University of Alberta Hospital
Edmonton, Alberta, Canada - St. Paul's Hospital
Vancouver, British Columbia, Canada - (and 9 more...)
|
3 |
NCT01745237 |
Recruiting |
Delayed-Enhancement Cardiovascular Magnetic Resonance in Patients With Sarcoidosis |
|
|
Observational |
|
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- cardiac mortality
- arrhythmic death
- Pulmonary mortality
- (and 5 more...)
|
500 |
All |
18 Years and older (Adult, Senior) |
NCT01745237 |
Pro00008224 DCMRC-8224a |
|
September 2002 |
December 2019 |
December 2019 |
December 10, 2012 |
February 13, 2018 |
|
- Duke University Medical Center
Durham, North Carolina, United States
|
4 |
NCT02829853 |
Recruiting |
Clinical and Genetic Study of Familial Sarcoidosis (SARCFAM) |
|
- Genetic: Genetic analysis by SANGER and WHOLE EXOME NEXT GENERATION SEQUENCING
|
Observational |
|
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- number of mutations founded in the IL34-TIAM gene
|
800 |
All |
8 Years to 80 Years (Child, Adult, Senior) |
NCT02829853 |
D50604 |
SARCFAM |
January 2008 |
September 2016 |
September 2016 |
July 12, 2016 |
July 12, 2016 |
|
- Hospices Civils de Lyon / Hopital Edouard Herriot
Lyon, France
|
5 |
NCT03265405 |
Recruiting |
Efficacy and Safety of Two Glucocorticoid Regimens in the Treatment of Sarcoidosis |
|
- Drug: Low dose prednisolone
- Drug: Medium dose prednisolone
|
Interventional |
Phase 4 |
- Postgraduate Institute of Medical Education and Research
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Relapse or treatment failure
- Mean time to relapse/treatment failure
- Response
- (and 9 more...)
|
86 |
All |
18 Years to 65 Years (Adult) |
NCT03265405 |
INT/IEC/2017/299 |
SARCORT |
April 1, 2017 |
March 31, 2022 |
March 31, 2022 |
August 29, 2017 |
August 31, 2017 |
|
- Postgraduate Institute of Medical Education and Research
Chandigarh, India
|
6 |
NCT02875756 |
Recruiting |
Effect of the Number of Needle Revolutions Inside the Node on the Diagnostic Yield of EBUS-TBNA in Sarcoidosis |
|
- Procedure: 10 revolutions
- Procedure: 20 revolutions
|
Interventional |
Phase 2 Phase 3 |
- Postgraduate Institute of Medical Education and Research
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Outcomes Assessor)
- Primary Purpose: Diagnostic
|
- Diagnostic yield of EBUS-TBNA as indicated by the presence of granuloma
- Adequacy of samples as indicated by the presence of lymphocytes
|
150 |
All |
18 Years to 85 Years (Adult, Senior) |
NCT02875756 |
NK/2232/study/1116 |
|
August 2016 |
September 2017 |
December 2017 |
August 23, 2016 |
August 23, 2016 |
|
- Post Graduate Institute of Medical Education and Research
Chandigarh, UT, India
|
7 |
NCT02546388 |
Recruiting |
Somatostatin Receptor Imaging in Patients With Suspected Cardiac Sarcoidosis |
|
- Drug: Indium-111 Pentreotide
|
Interventional |
Not Applicable |
- Marcelo F. Di Carli, MD, FACC
- Mallinckrodt
- Brigham and Women's Hospital
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Diagnostic
|
- Visual signal of OctreoScan or DOTATATE in the heart
- Early versus delayed imaging
- Correlate localization and number of increased foci
- Effect of Treatment
|
15 |
All |
18 Years to 90 Years (Adult, Senior) |
NCT02546388 |
2015P001421 |
|
October 2015 |
August 2018 |
August 2018 |
September 10, 2015 |
August 29, 2017 |
|
- Brigham and Women's Hospital
Boston, Massachusetts, United States
|
8 |
NCT02044939 |
Recruiting |
Pulmonary Rehabilitation in Patients With Sarcoidosis |
- Stage 4 Pulmonary Sarcoidosis
|
- Other: Pulmonary rehabilitation program
|
Interventional |
Not Applicable |
- University Hospital, Lille
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Prevention
|
- Daily activity assessed by time (in minutes) spent in moderate activity (superior to 2,5 MET)
- Daily activity assessed by time spent in moderate activity (superior to 2,5 MET)
- exercise capacity assessed by symptom-limited cardiopulmonary exercise test, 6 minutes walk test, endurance test on bicycle, St Etienne questionnaire, 6 minutes stepper test
- (and 6 more...)
|
150 |
All |
18 Years and older (Adult, Senior) |
NCT02044939 |
2011_23/1917 2012-A00347-36 |
|
July 10, 2012 |
June 2018 |
July 2018 |
January 24, 2014 |
May 19, 2017 |
|
- Clinique des Maladies Respiratoires, CHRU de LILLE
Lille, Nord, France - Service de Pneumologie, CH Béthune
Béthune, Pas de Calais, France - Service de Pneumologie, CH Arras
Arras, France - (and 8 more...)
|
9 |
NCT03140644 |
Recruiting |
SARCOLOWDOSE : Ultra-low Dose CT Scan and MRI in Thoracic Sarcoidosis |
|
- Other: Patients with thoracic sarcoidosis
|
Interventional |
Not Applicable |
- Rennes University Hospital
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Diagnostic
|
- Percentage of fibrosis within the 2 lungs (reticulations with or without honeycombing) in standard CT and ULD CT to study diagnostic agreement between these techniques
- Percentage of ground-glass opacity within the 2 lungs in standard CT and ULD CT
- Percentage of consolidation within the 2 lungs in standard CT and ULD CT
- (and 22 more...)
|
50 |
All |
18 Years and older (Adult, Senior) |
NCT03140644 |
2016-A01781-50 35RC16_9760 |
SARCOLOWDOSE |
May 16, 2017 |
May 16, 2019 |
November 16, 2019 |
May 4, 2017 |
August 28, 2017 |
|
|
10 |
NCT02812849 |
Recruiting |
Somatostatin Receptor Imaging in Cardiac Sarcoidosis |
|
|
Observational |
|
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Sensitivity to detect cardiac sarcoidosis
- Specificity to detect cardiac sarcoidosis
|
60 |
All |
18 Years and older (Adult, Senior) |
NCT02812849 |
0001 |
|
June 2016 |
November 2019 |
|
June 24, 2016 |
September 27, 2017 |
|
- Rigshospitalet
Copenhagen, Denmark
|
11 |
NCT02265874 |
Recruiting |
Nicotine Treatment for Pulmonary Sarcoidosis: A Clinical Trial Pilot Study |
|
- Drug: Habitrol
- Drug: Placebo to Habitrol
|
Interventional |
Phase 1 Phase 2 |
- Ohio State University
- The Cleveland Clinic
|
Other |
- Allocation: Randomized
- Intervention Model: Single Group Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Spirometry
- computed tomography (CT)
|
60 |
All |
18 Years to 75 Years (Adult, Senior) |
NCT02265874 |
2014H0291 |
|
October 2014 |
October 2019 |
October 2019 |
October 16, 2014 |
January 11, 2017 |
|
- Martha Morehouse Medical Pavilion 2050 Kenny Rd; Ste 2600
Columbus, Ohio, United States
|
12 |
NCT02298491 |
Recruiting |
CNS Sarcoidosis and Acthar Gel |
|
|
Interventional |
Phase 4 |
- University of Maryland
- Mallinckrodt
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Change in the total number of lesions
- Quality of life measures
- Quality of Life Measure
|
10 |
All |
Child, Adult, Senior |
NCT02298491 |
HP-00062490 |
|
May 2016 |
December 2017 |
December 2018 |
November 24, 2014 |
May 3, 2017 |
|
- University of Maryland, Baltimore
Baltimore, Maryland, United States
|
13 |
NCT03260556 |
Recruiting |
Pirfenidone for Progressive Fibrotic Sarcoidosis |
|
- Drug: Pirfenidone
- Drug: Placebos
|
Interventional |
Phase 4 |
- University of Cincinnati
- Royal Brompton & Harefield NHS Foundation Trust
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Treatment
|
- Time until clinical worsening (TCW)
- Change in forced vital capacity (FVC)
- Change in CPI
|
60 |
All |
18 Years to 90 Years (Adult, Senior) |
NCT03260556 |
2016-5706 |
PirFS |
September 27, 2017 |
December 31, 2019 |
March 30, 2020 |
August 24, 2017 |
September 28, 2017 |
|
- University of Cincinnati
Cincinnati, Ohio, United States
|
14 |
NCT02888080 |
Recruiting |
Study of Efficacy, Safety and Tolerability of ACZ885 (Canakinumab) in Patients With Pulmonary Sarcoidosis |
|
- Drug: ACZ885
- Drug: Placebo
|
Interventional |
Phase 2 |
- Novartis Pharmaceuticals
- Novartis
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Treatment
|
- Change between baseline and week 24 in pulmonary function as measured by spirometry
- Change between baseline and week 12 in pulmonary tissue inflammation as measured by [F-18]FDG-PET/CT
- Change from baseline in other parameters of pulmonary function testing
- (and 3 more...)
|
38 |
All |
18 Years to 80 Years (Adult, Senior) |
NCT02888080 |
CACZ885X2205 |
|
December 19, 2016 |
December 26, 2018 |
December 26, 2018 |
September 2, 2016 |
April 9, 2018 |
|
- Novartis Investigative Site
Birmingham, Alabama, United States - Novartis Investigative Site
Albany, New York, United States - Novartis Investigative Site
Cleveland, Ohio, United States - (and 5 more...)
|
15 |
NCT02625558 |
Recruiting |
Riociguat for Sarcoidosis Associated Pulmonary Hypertension |
|
- Drug: Riociguat
- Drug: Placebo
|
Interventional |
Phase 4 |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Time until clinical worsening
- Safety: adverse events
- Pulmonary function
- (and 2 more...)
|
60 |
All |
18 Years and older (Adult, Senior) |
NCT02625558 |
2014-7130 |
RioSAPH |
April 2015 |
April 2018 |
October 2018 |
December 9, 2015 |
December 9, 2015 |
|
- University of Cincinnati
Cincinnati, Ohio, United States
|
16 |
NCT03324503 |
Not yet recruiting |
A Study to Estimate the Effect Sizes of HRCT Endpoints in Response to Glucocorticoid Induction Therapy in Subjects With Pulmonary Sarcoidosis |
|
- Drug: Glucocorticoid (prednisone or prednisolone)
|
Interventional |
Phase 1 |
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Diagnostic
|
- Change from baseline in high-resolution computed tomography (HRCT)
|
24 |
All |
18 Years to 65 Years (Adult) |
NCT03324503 |
NDS-CP-001 U1111-1201-4544 2017-002001-34 |
|
October 31, 2017 |
November 30, 2018 |
November 30, 2018 |
October 27, 2017 |
October 27, 2017 |
|
|
17 |
NCT02920710 |
Not yet recruiting |
ACTHAR Therapy for Central Nervous System Sarcoidosis |
|
- Drug: Repository Corticotropin Injection
|
Interventional |
Phase 4 |
- The Cleveland Clinic
- Mallinckrodt
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Proportion of patients with clinically significant improvement - successful glucocorticoid tapering.
- Proportion of patients with clinically significant improvement - no need for escalation of other therapy.
|
20 |
All |
Child, Adult, Senior |
NCT02920710 |
ACTHAR CNS |
|
June 2018 |
July 2019 |
December 2019 |
September 30, 2016 |
February 21, 2018 |
|
- Cleveland Clinic Main Campus
Cleveland, Ohio, United States
|
18 |
NCT03145922 |
Recruiting |
Epigenetic Regulation of Altered T-cell Immunity in Sarcoidosis |
- Sarcoidosis
- Sarcoidosis, Pulmonary
|
- Other: Observational Study
|
Observational |
|
- University of California, San Francisco
- National Jewish Health
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Epigenomic Signature of Sarcoidosis
|
45 |
All |
18 Years to 85 Years (Adult, Senior) |
NCT03145922 |
15-18171 |
|
January 2016 |
January 2021 |
January 2026 |
May 9, 2017 |
May 9, 2017 |
|
- University of California, San Francisco (Parnassus)
San Francisco, California, United States
|
19 |
NCT03320070 |
Recruiting |
Pilot Study to Assess the Efficacy and Safety of H.P. Acthar® Gel in Subjects With Pulmonary Sarcoidosis |
|
- Drug: repository corticotropin injection
- Drug: Placebo
|
Interventional |
Phase 4 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Response will be evaluated by Sarcoidosis Treatment Score (STS)
|
100 |
All |
18 Years to 90 Years (Adult, Senior) |
NCT03320070 |
MNK14344100 |
|
January 24, 2018 |
November 2019 |
May 2020 |
October 25, 2017 |
April 17, 2018 |
|
- UAB Lung Health Center
Birmingham, Alabama, United States - University of Miami Miller School of Medicine
Miami, Florida, United States - Laporte County Institute For Clinical Research
Michigan City, Indiana, United States - (and 18 more...)
|
20 |
NCT02824419 |
Recruiting |
Imaging of Active Granulomas With [18F]FDG and Selected Inflammatory PET Tracers in Pulmonary Sarcoidosis |
|
- Drug: Methionine
- Drug: DOTANOC
|
Interventional |
Phase 2 Phase 3 |
- Turku University Hospital
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Diagnostic
|
- The detection of sarcoidotic lesion with C11-methionine or 68Ga-DOTANOC.
|
10 |
All |
18 Years and older (Adult, Senior) |
NCT02824419 |
T16/2015 |
|
May 2016 |
May 2017 |
December 2017 |
July 6, 2016 |
July 6, 2016 |
|
- Turku University Hospital
Turku, Varsinais-Suomi, Finland
|
21 |
NCT02024555 |
Recruiting |
Phase II Investigation of Antimycobacterial Therapy on Progressive, Pulmonary Sarcoidosis |
- Sarcoidosis; Antimycobacterial Therapy
|
- Drug: Levofloxacin
- Drug: Ethambutol
- Drug: Azithromycin
- (and 2 more...)
|
Interventional |
Phase 2 |
- Vanderbilt University
- National Heart, Lung, and Blood Institute (NHLBI)
- Vanderbilt University Medical Center
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Determine the effect of CLEAR therapy versus placebo on the change in percent predicted absolute forced vital capacity (FVC) in participants with pulmonary sarcoidosis, comparing baseline with performance after completion of 16 weeks of therapy.
- Radiographic improvement in sarcoidosis lung disease by frontal chest x-ray .
- Change in 6 minute walk distance, oxygen saturation and level of dyspnea
- (and 4 more...)
|
128 |
All |
18 Years and older (Adult, Senior) |
NCT02024555 |
R01HL117074 R01HL117074-01 |
|
March 2014 |
March 2019 |
May 2019 |
December 31, 2013 |
March 27, 2018 |
|
- Albany Medical Center
Albany, New York, United States - University of Cincinnati
Cincinnati, Ohio, United States - Cleveland Clinic
Cleveland, Ohio, United States - (and 3 more...)
|
22 |
NCT02540694 |
Recruiting |
EBUS vs EUS-B for Diagnosing Sarcoidosis |
- Sarcoidosis
- Endosonography
|
|
Interventional |
Not Applicable |
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
- Cook Medical
|
Other |
- Allocation: Randomized
- Intervention Model: Factorial Assignment
- Masking: Single (Outcomes Assessor)
- Primary Purpose: Diagnostic
|
- The granuloma detection rate of endobronchial (EBUS) guided sampling of intrathoracic lymph nodes compared to esophageal (EUS-B using the EBUS scope) guided sampling in patients with suspected sarcoidosis stage I/II.
- Sample quality of conventional 22G vs. 25G ProCore needles in patients with suspected sarcoidosis stage I/II.
|
350 |
All |
18 Years and older (Adult, Senior) |
NCT02540694 |
NL51598.018.15 |
|
May 2015 |
November 2017 |
June 2018 |
September 4, 2015 |
September 4, 2015 |
|
- Academic Medical Center
Amsterdam, Netherlands
|
23 |
NCT02356445 |
Recruiting |
Use of Immunosuppressive Therapy for Sarcoidosis |
|
|
Observational |
|
|
Other |
- Observational Model: Cohort
- Time Perspective: Retrospective
|
|
2000 |
All |
15 Years to 90 Years (Child, Adult, Senior) |
NCT02356445 |
UCincinnati |
|
November 2014 |
November 2018 |
December 2018 |
February 5, 2015 |
August 14, 2017 |
|
- University of Cincinnati
Cincinnati, Ohio, United States
|
24 |
NCT02643732 |
Recruiting |
Fatigue in Sarcoidosis - Treatment With Methylphenidate |
|
- Drug: Methylphenidate (overencapsulated)
- Drug: Placebo (Over-encapsulated tablet)
|
Interventional |
Not Applicable |
- University of East Anglia
- Clinical Research and Trials Unit (Norfolk & Norwich University Hospital, UK)
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Recruitment rate (Feasibility outcome)
- Number of potential participants excluded (Feasibility outcome)
- Number of participants dropping out/Participant retention rate (Feasibility outcome)
- (and 11 more...)
|
30 |
All |
18 Years and older (Adult, Senior) |
NCT02643732 |
170-11-15 |
FaST-MP |
November 2016 |
May 2018 |
July 2018 |
December 31, 2015 |
January 11, 2017 |
|
- Norfolk and Norwich University Hospital
Norwich, Norfolk, United Kingdom
|
25 |
NCT03356756 |
Recruiting |
PET MRI Study in Patients With Cardiac Sarcoidosis |
- Inflammatory Cardiomyopathy
- Sarcoidosis
|
- Diagnostic Test: simultaneous combined 18F-FDG PET and cardiac MRI imaging
|
Observational |
|
- University Health Network, Toronto
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- The incremental value of combined 18F-FDG PET and cardiac MRI imaging in the evaluation of patients with suspected cardiac sarcoidosis or cardiac inflammation
- The differences in circulating plasma biomarkers between cardiac with suspected cardiac sarcoidosis and healthy people
- The prognostic significance of PET-MRI imaging findings in patients with cardiac inflammation
|
60 |
All |
18 Years and older (Adult, Senior) |
NCT03356756 |
CAPCR 15-9933 |
|
June 27, 2016 |
December 31, 2018 |
December 31, 2019 |
November 29, 2017 |
December 2, 2017 |
|
- University Health Network
Toronto, Ontario, Canada
|
26 |
NCT03048097 |
Recruiting |
Optimizing Acquisition Parameters and Interpretive Methods of FDG-PET/CT With Rb-82 |
|
- Drug: Fluorodeoxyglucose
- Drug: Rubidium
- Diagnostic Test: FDG-PET/CT with Rb82 Myocardial Perfusion Imaging
|
Interventional |
Phase 2 |
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Diagnostic
|
- Visual interpretation of FDG uptake
- Severity of myocardial inflammation
- The extent of inflammation
|
15 |
All |
18 Years and older (Adult, Senior) |
NCT03048097 |
1512016912 |
|
February 1, 2017 |
December 31, 2018 |
December 31, 2018 |
February 9, 2017 |
February 9, 2017 |
|
- Yale New Haven Hospital
New Haven, Connecticut, United States
|
27 |
NCT03103490 |
Recruiting |
PET/MRI Imaging of Cardiac Sarcoidosis |
- Cardiac Sarcoidosis
- Myocardial Inflammation
|
|
Interventional |
Phase 2 |
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Diagnostic
|
- Number of participants with F18 FSPG Uptake on PET/MRI Fused Images Indicating Cardiac Involvement of Sarcoidosis
- Number of Participants with Evidence of Whole Body F18 FSPG Uptake on PET/MRI Fused Images Indicating Extra-cardiac Sarcoidosis
|
20 |
All |
18 Years and older (Adult, Senior) |
NCT03103490 |
IRB Protocol: 40376 |
|
August 2, 2017 |
April 2019 |
April 2020 |
April 6, 2017 |
April 12, 2018 |
|
- Stanford University
Stanford, California, United States
|
28 |
NCT02725177 |
Recruiting |
Ocular Sarcoidosis Open Label Trial of ACTHAR Gel |
- Ocular Sarcoidosis
- Panuveitis
- Anterior Uveitis
|
- Drug: Repository Corticotropin Injection
- Drug: Repository Corticotropin Injection -Treatment Extension
|
Interventional |
Not Applicable |
- The Cleveland Clinic
- Mallinckrodt
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Proportion of patients with clinically significant improvement in visual acuity
- Proportion of patients with clinically significant improvement in the resolution-intraocular inflammation
- Proportion of patients experiencing a tapering of ocular/oral steroids by at least 50%
- Proportion of patients with a clinically significant reduction-cystoid macular edema
|
20 |
All |
18 Years to 99 Years (Adult, Senior) |
NCT02725177 |
Ocular Sarcoidosis 15-1072 |
|
March 2016 |
December 2019 |
December 2019 |
March 31, 2016 |
February 12, 2018 |
|
- Cleveland Clinical Foundation
Cleveland, Ohio, United States
|
29 |
NCT03473964 |
Not yet recruiting |
(ACTH) for the Treatment of Sarcoid Uveitis |
|
|
Observational |
|
- John Huang, MD
- New England Retina Associates
|
Other |
- Observational Model: Case-Only
- Time Perspective: Retrospective
|
- Degree of aqueous and vitreous inflammatory cells-change is being assessed
- Degree of aqueous flare- change is being assessed
- Visual acuity- change is being assessed
- (and 3 more...)
|
10 |
All |
Child, Adult, Senior |
NCT03473964 |
1169914 |
ACTH |
April 1, 2018 |
March 2019 |
January 2020 |
March 22, 2018 |
March 22, 2018 |
|
- New England Retina Associates
Hamden, Connecticut, United States
|
30 |
NCT02523092 |
Not yet recruiting |
Use of CXCL9 as a Biomarker of Acthar Efficacy |
|
|
Interventional |
Phase 4 |
- University of California, San Francisco
- Mallinckrodt
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Decrease in blood CXCL9 levels by 50%
- Improvement in FVC by 5% of predicted
- Improvement in dyspnea score
|
14 |
All |
18 Years to 65 Years (Adult) |
NCT02523092 |
15-17300 |
Acthar |
October 2016 |
October 2017 |
March 2018 |
August 14, 2015 |
October 5, 2016 |
|
- University of California, San Francisco
San Francisco, California, United States
|
31 |
NCT03336736 |
Recruiting |
The Role of Physical Activity and Diet Within Pulmonary Sarcoidosis |
- Sarcoidosis
- Sarcoidosis, Pulmonary
- ILD
- Interstitial Lung Disease
|
- Diagnostic Test: Exercise
|
Observational |
|
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Daily physical activity measures against self-reported by tri-axial accelerometry
- Functional exercise capacity
- Muscle strength (isokinetic dynamometer)
- (and 11 more...)
|
15 |
All |
18 Years to 65 Years (Adult) |
NCT03336736 |
KingstonUSport |
|
November 7, 2017 |
December 15, 2017 |
February 28, 2018 |
November 8, 2017 |
November 8, 2017 |
|
- Applied & Human Sciences Human Performance Lab
Kingston Upon Thames, Surrey, United Kingdom - Kingston University London
Kingston upon Thames, Surrey, United Kingdom
|
32 |
NCT02989480 |
Recruiting |
PET-detected Myocardial Inflammation is a Characteristic of Cardiac Sarcoid But Not of ARVC |
- Sarcoidosis
- Arrhythmogenic Right Ventricular Cardiomyopathy
|
- Radiation: PET CT
- Other: Cardiac MRI
|
Observational |
|
- University of Aberdeen
- NHS Grampian
|
Other |
- Observational Model: Other
- Time Perspective: Prospective
|
- Myocardial inflammation or fibrosis by cardiac MRI and PET CT
|
20 |
All |
18 Years to 70 Years (Adult, Senior) |
NCT02989480 |
3/072/14 |
|
August 2015 |
July 2018 |
July 2018 |
December 12, 2016 |
October 25, 2017 |
|
- Aberdeen Royal Infirmary
Aberdeen, Aberdeenshire, United Kingdom
|
33 |
NCT03312712 |
Not yet recruiting |
Validation of the Analysis Methodology Behind the Use of Quantitative 18F-FDG PET/CT to Assess Lung Inflammation |
- Lung Inflammation
- Sarcoidosis
|
- Radiation: PET/CT scan
- Other: LPS Challenge
- Other: Saline Challenge
- Diagnostic Test: Blood and urine sampling
|
Observational |
|
- Cambridge University Hospitals NHS Foundation Trust
- GlaxoSmithKline
|
Other / Industry |
- Observational Model: Case-Control
- Time Perspective: Prospective
|
- Validation of 18F-FDG methodology used to assess lung inflammation in participants with sarcoidosis
- Pulmonary function tests
- Plasma biomarkers of inflammation
- Leukocyte count and activity from BAL fluid samples
|
36 |
All |
30 Years and older (Adult, Senior) |
NCT03312712 |
VERIFY |
VERIFY |
February 2018 |
November 2019 |
November 2019 |
October 18, 2017 |
January 9, 2018 |
|
|
34 |
NCT03346018 |
Recruiting |
Immunologic Markers for the Differential Diagnosis Between Uveitis-TBC and Uveitis-SARC (TBC-SARC) |
- Uveitis Tuberculous
- Uveitis Sarcoid
|
- Diagnostic Test: Analysis of aqueous humor and plasma samples
|
Observational |
|
- Arcispedale Santa Maria Nuova-IRCCS
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Identify, in the aqueous humor and in the blood of patients suffering from granulomatous uveitis the presence of immunologic markers that distinguish between uveitis of tuberculous etiology and uveitis by sarcoidosis
|
30 |
All |
18 Years to 90 Years (Adult, Senior) |
NCT03346018 |
2017/0103969 |
TBC-SARC |
November 3, 2017 |
August 30, 2019 |
December 30, 2019 |
November 17, 2017 |
December 6, 2017 |
|
- IRCCS/AUSL Reggio Emilia Hospital
Reggio Emilia, Italy
|
35 |
NCT02916459 |
Recruiting |
EBUS-TBNA vs Flex 19G EBUS-TBNA |
- Lymphadenopathy
- Lung Cancer
- Sarcoidosis
- Lymphoma
|
- Device: 21G EBUS-TBNA needle
- Device: Flexible 19G EBUS-TBNA needle
|
Interventional |
Not Applicable |
- Heidelberg University
- Olympus Corporation
|
Other / Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Outcomes Assessor)
- Primary Purpose: Diagnostic
|
- The difference in quality of diagnostic tissue obtained between the two study arms following 4 separate needle punctures per lymph node
- The difference between the two study arms in the percentage of lymph nodes sampled where enough tissue is obtained for complete immunohistochemical and genetic mutation analysis
- The difference in complication rates between the two study arms
- (and 4 more...)
|
250 |
All |
18 Years and older (Adult, Senior) |
NCT02916459 |
19G 1.1-2016 |
|
October 2016 |
September 2018 |
October 2018 |
September 27, 2016 |
February 7, 2017 |
|
- Department of Pneumology and Critical Care medicine
Heidelberg, BW, Germany
|
36 |
NCT02592837 |
Recruiting |
EBUS-TBNA vs Flex 19G EBUS-TBNA |
- Lymphadenopathy
- Lung Cancer
- Sarcoidosis
- Lymphoma
|
- Device: Flexible 19G EBUS-TBNA needle
- Device: 21G EBUS-TBNA needle
|
Interventional |
Not Applicable |
- Royal Brompton & Harefield NHS Foundation Trust
- Olympus Corporation
|
Other / Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Outcomes Assessor)
- Primary Purpose: Diagnostic
|
- The difference in quality of diagnostic tissue obtained between the two study arms following 4 separate needle punctures per lymph node
- The difference between the two study arms in the percentage of lymph nodes sampled where enough tissue is obtained for complete immunohistochemical and genetic mutation analysis.
- The difference in complication rates between the two study arms
- (and 4 more...)
|
250 |
All |
18 Years and older (Adult, Senior) |
NCT02592837 |
2015LF016B |
|
May 2016 |
March 2018 |
April 2018 |
October 30, 2015 |
November 28, 2016 |
|
- Royal Brompton Hospital
London, United Kingdom
|
37 |
NCT02497079 |
Recruiting |
Diagnostic Accuracy of Polymerase Chain Reaction for Mycobacterium Tuberculosis Using EBUS-TBNA Samples |
- Lymphadenopathy
- Tuberculosis
- Sarcoidosis
|
- Device: Nested PCR for formalin-fixed tissues
- Device: Nested PCR for fresh tissues
- Device: Real-time PCR for fresh tissues
|
Interventional |
Not Applicable |
- Pusan National University Hospital
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Diagnostic
|
- Number of participants who detected each polymerase chain reactions for Mycobacterium tuberculosis
|
100 |
All |
18 Years and older (Adult, Senior) |
NCT02497079 |
PNUH-P-1 |
|
July 2015 |
December 2018 |
December 2018 |
July 14, 2015 |
July 20, 2015 |
|
- Pusan National University Hospital
Busan, Korea, Republic of
|
38 |
NCT00470327 |
Recruiting |
A Study of the Natural Progression of Interstitial Lung Disease (ILD) |
- Interstitial Lung Diseases
- Idiopathic Pulmonary Fibrosis
- Sarcoidosis
|
|
Observational |
|
- University of Chicago
- Idiopathic Pulmonary Fibrosis Clinical Research Network
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Natural history of course of disease in patients with Interstitial lung disease (ILD)
|
4000 |
All |
18 Years and older (Adult, Senior) |
NCT00470327 |
14163A |
|
September 2005 |
December 2020 |
December 2025 |
May 7, 2007 |
September 11, 2017 |
|
- University of Chicago
Chicago, Illinois, United States
|
39 |
NCT02855658 |
Recruiting |
Modulation of Immunity-related Gene Expression Under the Chinese Herbal Formula SS-1 Treatment for Sjögren's Syndrome |
|
|
Interventional |
Phase 2 |
- China Medical University Hospital
- Chang Gung Memorial Hospital
- China Medical University, China
- National Research Program for Biopharmaceuticals, Taiwan
|
Other |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Ocular surface disease index (OSDI)
- EULAR Sjogren's syndrome patient reported index (ESSPRI)
- Sjogren's syndrome symptoms Questionnaire
- (and 6 more...)
|
90 |
All |
20 Years to 75 Years (Adult, Senior) |
NCT02855658 |
CMUH105-REC3-025 |
|
February 2014 |
October 2016 |
April 2017 |
August 4, 2016 |
August 4, 2016 |
|
- Taoyuan Chang Gung Memorial Hospital
Gueishan Township, Taiwan - China Medical University Hospital
Taichung, Taiwan
|
40 |
NCT00001532 |
Recruiting |
Role of Genetic Factors in the Development of Lung Disease |
- Cystic Fibrosis
- Sarcoidosis
- Tuberous Sclerosis
- Asthma
|
|
Observational |
|
- National Heart, Lung, and Blood Institute (NHLBI)
- Suburban Hospital
- National Institutes of Health Clinical Center (CC)
|
NIH / Other |
|
|
3600 |
All |
8 Years to 90 Years (Child, Adult, Senior) |
NCT00001532 |
960100 96-H-0100 |
|
June 6, 1996 |
|
|
November 4, 1999 |
April 4, 2018 |
|
- Suburban Hospital
Bethesda, Maryland, United States - National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States
|
41 |
NCT02452983 |
Recruiting |
Sertraline in Treatment of Low-Risk Myelodysplastic Syndrome |
- Myelodysplastic Syndromes
|
- Drug: Sertraline
- Procedure: Bone Marrow Aspirate/Biopsy
|
Interventional |
Phase 1 |
- Gustavo Rivero
- Baylor College of Medicine
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Hematological Improvement - minor (HI-minor)
- HI-minor response rate
- Individual rates of HI minor measurements: erythroid, neutrophil and platelet
- (and 4 more...)
|
30 |
All |
18 Years and older (Adult, Senior) |
NCT02452983 |
H-36160 |
SS1 |
May 2015 |
December 2018 |
June 2019 |
May 25, 2015 |
December 20, 2017 |
|
- Baylor College of Medicine
Houston, Texas, United States - Michael E. DeBakey VA Medical Center
Houston, Texas, United States
|
42 |
NCT02827734 |
Recruiting |
Evaluation of Novel Lung Function Parameters in Patients With Interstitial Lung Disease (ILD) |
- Pulmonary Healthy Controls
- Interstitial Lung Disease
- Idiopathic Pulmonary Fibrosis
- (and 3 more...)
|
- Device: multiple breath washout tests
- Device: impulse oscillometry
- Device: body plethysmography
|
Observational |
|
- Universitätsmedizin Mannheim
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- lung clearance index (LCI) as determined by multiple breath washout
- airway resistance and reactance (R5, X5, R-D5-20) as determined by impulse oscillometry
- repeatability of lung clearance index (LCI)
|
50 |
All |
18 Years and older (Adult, Senior) |
NCT02827734 |
MBW-ILD |
|
October 2015 |
November 2017 |
November 2017 |
July 11, 2016 |
February 8, 2017 |
|
- Universitätsmedizin Mannheim
Mannheim, Deutschland, Germany
|
43 |
NCT03455686 |
Not yet recruiting |
Exploring the Utility of Hyperpolarized 129Xe MRI in Healthy Volunteers and Patients With Lung Disease |
- Asthma
- Chronic Obstructive Pulmonary Disease
- Bronchiectasis
- (and 5 more...)
|
- Other: Hyperpolarized 129Xe MRI
|
Interventional |
Not Applicable |
- McMaster University
- St. Joseph's Healthcare Hamilton
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Basic Science
|
- Ventilation Defect Percent (VDP)
- Apparent Diffusion Coefficient (ADC)
- Signal-to-noise ratio (SNR)
|
60 |
All |
18 Years to 85 Years (Adult, Senior) |
NCT03455686 |
FIRH_Xe0001 |
|
March 2018 |
March 2023 |
March 2023 |
March 6, 2018 |
March 6, 2018 |
|
- Firestone Institute for Respiratory Health, St. Joseph's Healthcare
Hamilton, Ontario, Canada
|
44 |
NCT02789371 |
Recruiting |
Comparing of Modified Wet Suction Technique and Dry Suction Technique for EUS-FNA of Solid Occupying Lesions |
- Pancreas Neoplasms
- Lymphatic Metastasis
- Neoplasm Metastases
- (and 5 more...)
|
- Procedure: the first pass is made with 5ml suction technique
- Procedure: the first pass is made with modified wet suction technique
|
Interventional |
Not Applicable |
- Bin Cheng
- Huazhong University of Science and Technology
|
Other |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Single (Outcomes Assessor)
- Primary Purpose: Diagnostic
|
- the overall diagnostic accuracy of modified wet suction technique and 5ml dry suction technique to the solid occupying lesions
- the diagnostic accuracy of modified wet suction technique and 5ml dry suction technique to the benign and malignant solid occupying pancreatic lesions and non-pancreatic lesions respectively.
- Blood contamination and cellularity in specimens obtained by modified wet suction technique and 5ml dry suction technique
|
296 |
All |
18 Years to 80 Years (Adult, Senior) |
NCT02789371 |
S135 |
|
May 2016 |
February 2018 |
March 2018 |
June 3, 2016 |
June 7, 2016 |
|
- Tongji hospital, Tongji Medical College, Huazhong University of Science and Technology
Wuhan, Hubei, China
|
45 |
NCT02656381 |
Recruiting |
Uveitis/Intraocular Inflammatory Disease Biobank (iBank) |
|
|
Observational |
|
- National Eye Institute (NEI)
- National Institutes of Health Clinical Center (CC)
|
NIH |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- The clinical data and samples from this study will be used to test for interaction of key parameters of phenotype with genetic variants and other biomarkers identified from biospecimens.
- Secondary outcomes will include the number and severity of systemic and ocular adverse events among participants who use systemic immunosuppression.
|
600 |
All |
8 Years and older (Child, Adult, Senior) |
NCT02656381 |
160046 16-EI-0046 |
|
January 13, 2016 |
January 4, 2036 |
January 4, 2036 |
January 14, 2016 |
April 4, 2018 |
|
- National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States
|